The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.
CD155, or poliovirus receptor (PVR), has recently emerged as a pro-tumorigenic antigen, overexpressed on GBM and contributing to increased GBM migration and aggressiveness. CD155 has also been established as an immunomodulatory receptor, able to both activate NK cells through interactions with CD226 (DNAM-1) and CD96 and inhibit them through interaction with TIGIT.
|Expressed gene:||PDL1、CD155、TCR Activator|
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||F12K+10%FBS+600ug/ml hygromycin+2ug/ml puromycin+5ug/ml blasticidin|
|Application(s):||Functional(Report Gene) Assay|
|III. Representative Data|
Figure 1. Dose Response of Blocking Antibodies in PD-1/TIGIT Dual Effector Reporter Cells (Clone 7) With PD-L1&CD155/ TCR Activator - CHO Cells.
邮箱： firstname.lastname@example.org （销售部） email@example.com （技术部）